Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Additional Blood Test Enhances Diagnostic Sensitivity of Relapse Detection and Predicts Survivals in High-risk Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA

NCT03981224 is registered in ClinicalTrials.gov with Taichung Veterans General Hospital as lead sponsor.

NCT NCT03981224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03981224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Additional Blood Test Enhances Diagnostic Sensitivity of Relapse Detection and Predicts Survivals in High-risk Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA
Lead sponsor
Taichung Veterans General Hospital
Phase
Observational
Overall status
Completed
Start date
May 2, 2012
Completion date
May 1, 2013
Enrollment
706 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma